In a recent study, it was discovered that pyroptosis of fewer than 15% of tumor cells was adequate to eradicate the entire grafted 4T1 mammary tumor.[26] However, it's uncertain whether the new Arf1 inhibitors specifically target cancer stem cells (CSCs) to induce systemic anti‐tumor immunity due to the ongoing debate about CSC markers and their identity. Here, ARF1 is linked to neoplasm.